BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

818 related articles for article (PubMed ID: 24577808)

  • 21. Eosinophilic myeloid disorders.
    Noel P
    Semin Hematol; 2012 Apr; 49(2):120-7. PubMed ID: 22449622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders.
    Kelemen K; Saft L; Craig FE; Orazi A; Nakashima M; Wertheim GB; George TI; Horny HP; King RL; Quintanilla-Martinez L; Wang SA; Rimsza LM; Reichard KK
    Am J Clin Pathol; 2021 Feb; 155(2):179-210. PubMed ID: 33367563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.
    Patterer V; Schnittger S; Kern W; Haferlach T; Haferlach C
    Ann Hematol; 2013 Jun; 92(6):759-69. PubMed ID: 23400675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia.
    Lierman E; Cools J
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1295-304. PubMed ID: 19761433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel acquired cryptic three-way translocation t(2;11;5)(p21.3;q13.5;q23.2) with a submicroscopic deletion at 11p14.3 in an adult with hypereosinophilic syndrome.
    Kjeldsen E
    Exp Mol Pathol; 2015 Aug; 99(1):50-5. PubMed ID: 25962659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blood and Bone Marrow Evaluation for Eosinophilia.
    Boyer DF
    Arch Pathol Lab Med; 2016 Oct; 140(10):1060-7. PubMed ID: 27684977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders.
    Valent P
    Blood Rev; 2009 Jul; 23(4):157-65. PubMed ID: 19246139
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Causes of hypereosinophilia in 100 consecutive patients.
    Moller D; Tan J; Gauiran DTV; Medvedev N; Hudoba M; Carruthers MN; Dehghan N; van den Berghe J; Bruyère H; Chen LYC
    Eur J Haematol; 2020 Sep; 105(3):292-301. PubMed ID: 32364630
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia].
    Chrobák L; Voglová J
    Vnitr Lek; 2005 Dec; 51(12):1385-93. PubMed ID: 16430106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The hypereosinophilic syndrome: idiopathic or not, that is the question.
    Cools J
    Haematologica; 2005 May; 90(5):582-4. PubMed ID: 15921372
    [No Abstract]   [Full Text] [Related]  

  • 31. Hypereosinophilic syndrome, chronic eosinophilic leukemia, and mast cell disease.
    Pardanani A; Verstovsek S
    Cancer J; 2007; 13(6):384-91. PubMed ID: 18032976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [New insights into hypereosinophilic syndromes].
    Bletry O; Kahn JE; Ackermann F; Charles P; Legrand F
    Bull Acad Natl Med; 2010 Mar; 194(3):547-59; discussion 559-60. PubMed ID: 21171248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review.
    Savage N; George TI; Gotlib J
    Int J Lab Hematol; 2013 Oct; 35(5):491-500. PubMed ID: 23489324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
    Schwartz LB; Sheikh J; Singh A
    Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in diagnosis and treatment of eosinophilia.
    Sheikh J; Weller PF
    Curr Opin Hematol; 2009 Jan; 16(1):3-8. PubMed ID: 19057198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular classification and pathogenesis of eosinophilic disorders: 2005 update.
    Gotlib J
    Acta Haematol; 2005; 114(1):7-25. PubMed ID: 15995322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.
    Tefferi A; Thiele J; Vardiman JW
    Cancer; 2009 Sep; 115(17):3842-7. PubMed ID: 19472396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Myeloproliferative hypereosinophilic syndrome revealed by bipolar mucosal ulcerations].
    Isvy-Joubert A; Hickman G; Flageul B; Battistella M; Bagot M; Galicier L; Petit A
    Ann Dermatol Venereol; 2012 Oct; 139(10):636-40. PubMed ID: 23122377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia.
    Cilloni D; Messa F; Martinelli G; Gottardi E; Arruga F; Defilippi I; Carturan S; Messa E; Fava M; Giugliano E; Rosso V; Catalano R; Merante S; Nicoli P; Rondoni M; Ottaviani E; Soverini S; Tiribelli M; Pane F; Baccarani M; Saglio G
    Leukemia; 2007 Jul; 21(7):1442-50. PubMed ID: 17508006
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blood eosinophilia: a new paradigm in disease classification, diagnosis, and treatment.
    Tefferi A
    Mayo Clin Proc; 2005 Jan; 80(1):75-83. PubMed ID: 15667033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.